Capital Group Investment Management PTE. LTD. Raises Stock Position in Amgen Inc. $AMGN

Key Points

• Capital Group Investment Management PTE. LTD. raised its stake in Amgen by 93.4% in Q3, buying 5,666 shares to hold 11,732 shares valued at about $3.31 million.
• Amgen beat recent quarterly estimates with $5.29 EPS and $9.87 billion in revenue (revenue +8.6% YoY) and set FY2026 guidance of 21.60–23.00 EPS.
• Analyst sentiment is mixed — the consensus is an average rating of Hold with an average target price of $354.17, though several firms have raised targets (e.g., Wells Fargo to $375 and UBS to $390) and the street breakdown is 1 Strong Buy, 14 Buy, 12 Hold and 2 Sell.

Capital Group Investment Management PTE. LTD. grew its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 93.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,732 shares of the medical research company's stock after buying an additional 5,666 shares during the period. Capital Group Investment Management PTE. LTD.'s holdings in Amgen were worth $3,311,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Evelyn Partners Investment Management LLP acquired a new position in Amgen in the second quarter valued at approximately $32,000. Howard Hughes Medical Institute acquired a new stake in Amgen during the second quarter worth $32,000. Cloud Capital Management LLC acquired a new stake in Amgen during the third quarter worth $34,000. AXS Investments LLC purchased a new stake in Amgen in the third quarter valued at $42,000. Finally, Winnow Wealth LLC purchased a new stake in Amgen in the third quarter valued at $47,000. Institutional investors and hedge funds own 76.50% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on AMGN. Weiss Ratings reiterated a "buy (b)" rating on shares of Amgen in a report on Monday, December 29th. Wells Fargo & Company upped their target price on shares of Amgen from $325.00 to $375.00 and gave the company an "equal weight" rating in a research report on Thursday, February 19th. Wall Street Zen lowered shares of Amgen from a "buy" rating to a "hold" rating in a research note on Saturday, February 21st. TD Cowen reissued a "buy" rating on shares of Amgen in a research note on Wednesday, February 4th. Finally, UBS Group upped their price objective on shares of Amgen from $380.00 to $390.00 and gave the stock a "buy" rating in a report on Monday, January 26th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $354.17.

Amgen Price Performance

AMGN opened at $376.97 on Tuesday. The stock's 50-day moving average price is $354.21 and its 200 day moving average price is $323.38. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $391.29. The firm has a market cap of $203.21 billion, a price-to-earnings ratio of 26.49, a PEG ratio of 3.67 and a beta of 0.45. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. The company had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.Amgen's revenue was up 8.6% compared to the same quarter last year. During the same period in the previous year, the company posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, sell-side analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.7%. Amgen's payout ratio is 70.84%.

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.